Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization

Journal of General Virology

Volumn 88, Issue 1, 2007, Pages 61-70

  Naito, Toshio ^a,d   Kaneko, Yutaro ^b   Kozbor, Danuta ^a,c  

^a TEMPLE UNIVERSITY   (United States)

^b KINKI UNIVERSITY   (Japan)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; LIPOSOME; MACROGOL; TRESYLMONOMETHOXYPOLYETHYLENE GLYCOL; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; COVALENT BOND; GENE TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LIPID MEMBRANE; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TUMOR IMMUNITY; VACCINIA VIRUS; VIRUS INFECTIVITY; VIRUS RECOMBINANT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; GENETIC VECTORS; HIV-1; IMMUNITY, CELLULAR; IMMUNIZATION; LIPOSOMES; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; POXVIRIDAE; VACCINIA VIRUS; VACCINIA VIRUS ANKARA; VARIOLA VIRUS;

EID: 33846156204     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.82216-0     Document Type: Article

References (48)

1. Abacioglu, Y. H., Fouts, T. R., Laman, J. D., Claassen, E., Pincus, S. H., Moore, J. P., Roby, C. A., Kamin-Lewis, R. & Lewis, G. K. (1994). Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 10, 371-381.
2. Bangham, A. D. (1963). Physical structure and behavior of lipids and lipid enzymes. Adv Lipid Res 64, 65-104.
3. Belyakov, I. M., Wyatt, L. S., Ahlers, J. D., Earl, P., Pendleton, C. D., Kelsall, B. L., Strober, W., Moss, B. & Berzofsky, J. A. (1998). Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J Virol 72, 8264-8272.
4. Belyakov, I. M., Moss, B., Strober, W. & Berzofsky, J. A. (1999). Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci U S A 96, 4512-4517.
5. Belyakov, I. M., Earl, P., Dzutsev, A., Kuznetsov, V. A., Lemon, M., Wyatt, L. S., Snyder, J. T., Ahlers, J. D., Franchini, G. & other authors (2003). Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 100, 9458-9463.
6. Belyakov, I. M., Hammond, S. A., Ahlers, J. D., Glenn, G. M. & Berzofsky, J. A. (2004). Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 113, 998-1007.
7. Bender, B. S., Rowe, C. A., Taylor, S. F., Wyatt, L. S., Moss, B. & Small, P. A., Jr (1996). Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 70, 6418-6424.
8. Chen, S. C., Jones, D. H., Fynan, E. F., Farrar, G. H., Clegg, J. C. S., Greenberg, H. B. & Herrmann, J. E. (1998). Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 72, 5757-5761.
9. Childers, N. K., Zhang, S. S. & Michalek, S. M. (1994). Oral immunization of humans with dehydrated liposomes containing Streptococcus mutans glucosyltransferase induces salivary immunoglobulin A2 antibody responses. Oral Microbiol Immunol 9, 146-153.
10. Cooney, E. L., Collier, A. C., Greenberg, P. D., Coombs, R. W., Zarling, J., Arditti, D. E., Hoffman, M. C., Hu, S.-L. & Corey, L. (1991). Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337, 567-572.
11. Czerkinsky, C., Anjuere, F., McGhee, J. R., George-Chandy, A., Holmgren, J., Kieny, M. P., Fujiyashi, K., Mestecky, J. F., Pierrefite-Carle, V. & other authors (1999). Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev 170, 197-222.
12. Delgado, C., Patel, J. N., Francis, G. E. & Fisher, D. (1990). Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride: characterization of the conjugate by partitioning in aqueous two-phase systems. Biotechnol Appl Biochem 12, 119-128.
13. Fenner, F. (1989). Risks and benefits of vaccinia vaccine use in the worldwide smallpox eradication campaign. Res Virol 140, 465-466.
14. Francis, G. E., Fisher, D., Delgado, C., Malik, F., Gardiner, A. & Neale, D. (1998). PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int J Hematol 68, 1-18.
15. Fuertges, F. & Abuchowski, A. (1990). The clinical efficacy of poly(ethylene glycol)-modified proteins. J Control Release 11, 139-148.
16. Fuller, D. H., Rajakumar, P. A., Wilson, L. A., Trichel, A. M., Fuller, J. T., Shipley, T., Wu, M. S., Weis, K., Rinaldo, C. R. & other authors (2002). Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 76, 3309-3317.
17. Gaidarov, I., Santini, F., Warren, R. A. & Keen, J. H. (1999). Spatial control of coated-pit dynamics in living cells. Nat Cell Biol 1, 1-7.
18. Gherardi, M. M. & Esteban, M. (1999). Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants. Vaccine 17, 1074-1083.
19. Gregoriadis, G. & Ryman, B. E. (1972). Fate of protein-containing liposomes injected into rats. An approach to the treatment of storage diseases. Eur J Biochem 24, 485-491.
20. Gurunathan, S., Wu, C.-Y., Freidag, B. L. & Seder, R. A. (2000). DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 12, 442-447.
21. Hanke, T., Blanchard, T. J., Schneider, J., Hannan, C. M., Becker, M., Gilbert, S. C., Hill, A. V. S., Smith, G. L. & McMichael, A. (1998). Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439-445.
22. Harasym, T. O., Tardi, P., Longman, S. A., Ansell, S. M., Bally, M. B., Cullis, P. R. & Choi, L. S. L. (1995). Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem 6, 187-194.
23. Hedley, M. L., Curley, J. & Urban, R. (1998). Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 4, 365-368.
24. Ishii, N., Fukushima, J., Kaneko, T., Okada, E., Tani, K., Tanaka, S. I., Hamajima, K., Xin, K.-Q., Kawamoto, S. & other authors (1997). Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 13, 1421-1428.
25. Jones, D. H., Corris, S., McDonald, S., Clegg, J. C. S. & Farrar, G. H. (1997). Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 15, 814-817.
26. Kaneko, H., Bednarek, I., Wierzbicki, A., Kiszka, I., Dmochowski, M., Wasik, T. J., Kaneko, Y. & Kozbor, D. (2000). Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 267, 8-16.
27. Kiszka, I., Kmieciak, D., Gzyl, J., Naito, T., Bolesta, E., Sieron, A., Singh, S. P., Srinivasan, A., Trinchieri, G. & other authors (2002). Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates. J Virol 76, 4222-4232.
28. + cytotoxic T lymphocytes in mice. Virology 227, 353-360.
29. Kresina, T. F. & Mathieson, B. (1999). Human immunodeficiency virus type 1 infection, mucosal immunity, and pathogenesis and extramural research programs at the National Institutes of Health. J Infect Dis 179 (Suppl. 3), S392-S396.
30. Lasic, D. D. (1998). Novel applications of liposomes. Trends Biotechnol 16, 307-321.
31. Malik, F., Delgado, C., Knusli, C., Irvine, A. E., Fisher, D. & Francis, G. E. (1992). Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity. Exp Hematol 20, 1028-1035.
32. Mayr, A., Stickl, H., Muller, H. K., Danner, K. & Singer, H. (1978). The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. Zentralbl Bakteriol 167, 375-390 (in German).
33. McGhee, J. R. & Mestecky, J. (1990). In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens. Infect Dis Clin North Am 4, 315-341.
34. Mestecky, J. & Eldridge, J. H. (1991). Targeting and controlled release of antigens for the effective induction of secretory antibody responses. Curr Opin Immunol 3, 492-495.
35. Meyer, H., Sutter, G. & Mayr, A. (1991). Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72, 1031-1038.
36. O'Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., Smith, A. E. & Francis, G. E. (1999). PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 10, 1349-1358.
37. KU2 RNA levels. J Virol 80, 3732-3742.
38. Schneider, J., Gilbert, S. C., Blanchard, T. J., Hanke, T., Robson, K. J., Hannan, C. M., Becker, M., Sinden, R., Smith, G. L. & Hill, A. V. (1998). Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4, 397-402.
39. Senior, J., Delgado, C., Fisher, D., Tilcock, C. & Gregoriadis, G. (1991). Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta 1062, 77-82.
40. + T-cell peptide epitope of vaccinia and variola viruses. J Virol 78, 7052-7060.
41. Sutter, G. & Moss, B. (1992). Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Nalt Acad Sci U S A 89, 10847-10851.
42. Sutter, G. & Moss, B. (1995). Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand 84, 195-200.
43. + cytotoxic T lymphocytes by free antigenic peptide: a self-veto mechanism? J Exp Med 183, 879-889.
44. Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J.-C., Cox, W. I., Davis, S. W., van der Hoeven, J., Meignier, B. & other authors (1992). NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232.
45. Wierzbicki, A., Kiszka, L, Kaneko, H., Kmieciak, D., Wasik, T. J., Gzyl, J., Kaneko, Y. & Kozbor, D. (2002). Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein. Vaccine 20, 1295-1307.
46. Wyatt, L. S., Moss, B. & Rozenblatt, S. (1995). Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 210, 202-205.
47. Wyatt, L. S., Shors, S. T., Murphy, B. R. & Moss, B. (1996). Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14, 1451-1458.
48. Zalipsky, S. (1993). Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. Bioconjug Chem 4, 296-299.